Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMCOpen access

Effects of orally administered cetylated fatty acids on symptoms and functional capacity in patients with knee osteoarthritis: results of a randomized, double-blind, placebo-controlled study

Zodeleva M., Pochkhua N., Rossato MS., Arziani E.

Randomized Controlled Trial with a reported sample of 60 on Knee Osteoarthritis, Osteoarthritis, published in Eur J Clin Nutr (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Eur J Clin Nutr (2025)
Reported sample size
60
Source database
Europe PMC
PMID
40855215
PMCID
PMC12580315
DOI
10.1038/s41430-025-01656-4

Abstract (original English)

Background/objectives The development and implementation of new treatments for knee osteoarthritis in routine practice remains an unmet need. The aim of this study was to assess the efficacy and safety of a Cetylated Fatty Acids (CFA)-based dietary supplement in patients with knee osteoarthritis (OA), a prevalent and difficult-to-treat condition. Subjects/methods 60 patients (mean age: 66.0 ± 7.7 years, 85% female) with grade 3-4 knee osteoarthritis and a pain intensity of > 4 cm on the visual analog scale (VAS) were enrolled and randomized in a 1:1 ratio to receive either 1.5 g of oral CFA or a placebo for 60 days. The primary outcome was the change in pain intensity (VAS), secondary outcomes included changes in range of motion (ROM), in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the safety profile of the food supplement. Results After 60 days of CFA assumption, the mean reduction in pain intensity (VAS) was -1.7 cm (95% CI [-2.0, -1.4]), showing a statistically significant difference compared to placebo (-0.6 cm, 95% CI [-1.0, -0.2]; p Conclusion In patients with knee osteoarthritis, incorporating a CFA oral supplement into the treatment regimen provides superior efficacy in pain relief and range of motion improvement compared to placebo, while maintaining a favorable safety profile.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansOsteoarthritis, KneeFatty AcidsPain MeasurementRange of Motion, ArticularTreatment OutcomeAdministration, OralDouble-Blind MethodDietary SupplementsAged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research